Circulation. 2003;107:2850-2856
Published online before print June 2, 2003, doi: 10.1161/01.CIR.0000075270.13497.2B
Published online before print June 2, 2003, doi: 10.1161/01.CIR.0000075270.13497.2B
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:2850.)
© 2003 American Heart Association, Inc.
Basic Science Reports |
Transgenic Mice Overexpressing Mutant PRKAG2 Define the Cause of Wolff-Parkinson-White Syndrome in Glycogen Storage Cardiomyopathy
From the Department of Genetics, Harvard Medical School and Howard Hughes Medical Institute (M.A., I.P.M., F.A., G.H.L., P.G.B., J.P.S., A.P., C.E.S., J.G.S.), the Department of Pathology and Cardiac Registry, Children’s Hospital, and Harvard Medical School (I.P.M., A.R.P.-A.), the Department of Cardiology, Children’s Hospital and Department of Pediatrics, Harvard Medical School (V.V.P., C.T.M., C.I.B.), Boston University Medical Center, Myocardial Biology Unit (D.B.S., X.X.G.), and the Division of Cardiology, Brigham and Women’s Hospital (C.E.S.), Boston, Mass; the Molecular Cardiology Research Center and Section of Cardiac Electrophysiology, University of Pennsylvania, Philadelphia (V.V.P.); St Vincent’s Institute of Medical Research, Victoria, Australia (M.W., D.S.); and the Departments of Anesthesiology and Pharmacology (S.K.) and Medicine, Pharmacology, Molecular Physiology, and Biophysics (D.M.R.), Vanderbilt University School of Medicine, Nashville, Tenn.
Correspondence to Jonathan Seidman, PhD, Department of Genetics, Alpert Room 533, Harvard Medical School, 200 Longwood Ave, Boston, MA 02115. E-mail seidman{at}rascal.med.harvard.edu
Background— Mutations in the 
2 subunit (PRKAG2) of AMP-activated protein kinase produce an unusual human cardiomyopathy characterized by ventricular hypertrophy and electrophysiological abnormalities: Wolff-Parkinson-White syndrome (WPW) and progressive degenerative conduction system disease. Pathological examinations of affected human hearts reveal vacuoles containing amylopectin, a glycogen-related substance.
Methods and Results— To elucidate the mechanism by which PRKAG2 mutations produce hypertrophy with electrophysiological abnormalities, we constructed transgenic mice overexpressing the PRKAG2 cDNA with or without a missense N488I human mutation. Transgenic mutant mice showed elevated AMP-activated protein kinase activity, accumulated large amounts of cardiac glycogen (30-fold above normal), developed dramatic left ventricular hypertrophy, and exhibited ventricular preexcitation and sinus node dysfunction. Electrophysiological testing demonstrated alternative atrioventricular conduction pathways consistent with WPW. Cardiac histopathology revealed that the annulus fibrosis, which normally insulates the ventricles from inappropriate excitation by the atria, was disrupted by glycogen-filled myocytes. These anomalous microscopic atrioventricular connections, rather than morphologically distinct bypass tracts, appeared to provide the anatomic substrate for ventricular preexcitation.
Conclusions— Our data establish PRKAG2 mutations as a glycogen storage cardiomyopathy, provide an anatomic explanation for electrophysiological findings, and implicate disruption of the annulus fibrosis by glycogen-engorged myocytes as the cause of preexcitation in Pompe, Danon, and other glycogen storage diseases.
Key Words: kinases • glycogen storage disease • excitation • arrhythmia • hypertrophy
This article has been cited by other articles:
 |
|
 |
|
  A. C.T. Ha, J. M. Renaud, R. A. deKemp, S. Thorn, J. DaSilva, L. Garrard, K. Yoshinaga, A. Abraham, M. S. Green, R. S.B. Beanlands, et al. In Vivo Assessment of Myocardial Glucose Uptake by Positron Emission Tomography in Adults With the PRKAG2 Cardiac Syndrome Circ Cardiovasc Imaging, November 1, 2009; 2(6): 485 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Folmes, A. Y.M. Chan, D. P.Y. Koonen, T. C. Pulinilkunnil, I. Baczko, B. E. Hunter, S. Thorn, M. F. Allard, R. Roberts, M. H. Gollob, et al. Distinct Early Signaling Events Resulting From the Expression of the PRKAG2 R302Q Mutant of AMPK Contribute to Increased Myocardial Glycogen Circ Cardiovasc Genet, October 1, 2009; 2(5): 457 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Steinberg and B. E. Kemp AMPK in Health and Disease Physiol Rev, July 1, 2009; 89(3): 1025 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al. Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation' Europace, July 1, 2009; 11(7): 860 - 885. [Full Text] [PDF]
|
|
|
|
 |
|
 S R Lalani, J V Thakuria, G F Cox, X Wang, W Bi, M S Bray, C Shaw, S W Cheung, A C Chinault, B A Boggs, et al. 20p12.3 microdeletion predisposes to Wolff-Parkinson-White syndrome with variable neurocognitive deficits J. Med. Genet., March 1, 2009; 46(3): 168 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kaludercic, C. Reggiani, and N. Paolocci Genes, Geography and Geometry: The "Critical Mass" in Hypertrophic Cardiomyopathy J. Mol. Diagn., January 1, 2009; 11(1): 12 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst CHAPTER 29 Atrial Fibrillation ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Tan, A. C. van der Wal, M. E. Campian, H. H. Kruyswijk, B. ten Hove Jansen, D.-J. van Doorn, H. J. Oskam, A. E. Becker, and A. A.M. Wilde Nodoventricular Accessory Pathways in PRKAG2-Dependent Familial Preexcitation Syndrome Reveal a Disorder in Cardiac Development Circ Arrhythm Electrophysiol, October 1, 2008; 1(4): 276 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Watkins, H Ashrafian, and W J McKenna The genetics of hypertrophic cardiomyopathy: Teare redux Heart, October 1, 2008; 94(10): 1264 - 1268. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Momcilovic, S. H. Iram, Y. Liu, and M. Carlson Roles of the Glycogen-binding Domain and Snf4 in Glucose Inhibition of SNF1 Protein Kinase J. Biol. Chem., July 11, 2008; 283(28): 19521 - 19529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Young AMP-Activated Protein Kinase Conducts the Ischemic Stress Response Orchestra Circulation, February 12, 2008; 117(6): 832 - 840. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mayr, S. Yusuf, G. Weir, Y.-L. Chung, U. Mayr, X. Yin, C. Ladroue, B. Madhu, N. Roberts, A. De Souza, et al. Combined metabolomic and proteomic analysis of human atrial fibrillation. J. Am. Coll. Cardiol., February 5, 2008; 51(5): 585 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Wolf, M. Arad, F. Ahmad, A. Sanbe, S. A. Bernstein, O. Toka, T. Konno, G. Morley, J. Robbins, J.G. Seidman, et al. Reversibility of PRKAG2 Glycogen-Storage Cardiomyopathy and Electrophysiological Manifestations Circulation, January 15, 2008; 117(2): 144 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Folmes, L. A. Witters, M. F. Allard, M. E. Young, and J. R. B. Dyck The AMPK {gamma}1 R70Q mutant regulates multiple metabolic and growth pathways in neonatal cardiac myocytes Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3456 - H3464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Charron, M. Genest, P. Richard, M. Komajda, and G. Pochmalicki A familial form of conduction defect related to a mutation in the PRKAG2 gene Europace, August 1, 2007; 9(8): 597 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Arad, C. E. Seidman, and J.G. Seidman AMP-Activated Protein Kinase in the Heart: Role During Health and Disease Circ. Res., March 2, 2007; 100(4): 474 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. W. Dolinsky and J. R. B. Dyck Role of AMP-activated protein kinase in healthy and diseased hearts Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2557 - H2569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Xie, D. Zhang, J. R. B. Dyck, Y. Li, H. Zhang, M. Morishima, D. L. Mann, G. E. Taffet, A. Baldini, D. S. Khoury, et al. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway PNAS, November 14, 2006; 103(46): 17378 - 17383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bayrak, E. Komurcu-Bayrak, B. Mutlu, G. Kahveci, Y. Basaran, and N. Erginel-Unaltuna Ventricular pre-excitation and cardiac hypertrophy mimicking hypertrophic cardiomyopathy in a Turkish family with a novel PRKAG2 mutation Eur J Heart Fail, November 1, 2006; 8(7): 712 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, D. L. Coven, E. J. Miller, X. Hu, M. E. Young, D. Carling, A. J. Sinusas, and L. H. Young Activation of AMPK {alpha}- and {gamma}-isoform complexes in the intact ischemic rat heart Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1927 - H1934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yu, M. F. Hirshman, N. Fujii, J. M. Pomerleau, L. E. Peter, and L. J. Goodyear Muscle-specific overexpression of wild type and R225Q mutant AMP-activated protein kinase {gamma}3-subunit differentially regulates glycogen accumulation Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E557 - E565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. B. Dyck and G. D. Lopaschuk AMPK alterations in cardiac physiology and pathology: enemy or ally? J. Physiol., July 1, 2006; 574(1): 95 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Davies, D. J. Wells, K. Liu, H. R. Whitrow, T. D. Daniel, R. Grignani, C. A. Lygate, J. E. Schneider, G. Noel, H. Watkins, et al. Characterization of the role of {gamma}2 R531G mutation in AMP-activated protein kinase in cardiac hypertrophy and Wolff-Parkinson-White syndrome Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1942 - H1951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Hardie and K. Sakamoto AMPK: A Key Sensor of Fuel and Energy Status in Skeletal Muscle Physiology, February 1, 2006; 21(1): 48 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hattori, K. Akimoto, T. Nishikimi, H. Matsuoka, and K. Kasai Activation of AMP-Activated Protein Kinase Enhances Angiotensin II-Induced Proliferation in Cardiac Fibroblasts Hypertension, February 1, 2006; 47(2): 265 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Roberts Genomics and Cardiac Arrhythmias J. Am. Coll. Cardiol., January 3, 2006; 47(1): 9 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. J. Kang Cardiac Hypertrophy: A Risk Factor for QT-Prolongation and Cardiac Sudden Death Toxicol Pathol, January 1, 2006; 34(1): 58 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Wolf, I. P. G. Moskowitz, S. Arno, D. M. Branco, C. Semsarian, S. A. Bernstein, M. Peterson, M. Maida, G. E. Morley, G. Fishman, et al. Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia PNAS, December 13, 2005; 102(50): 18123 - 18128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ahmad, M. Arad, N. Musi, H. He, C. Wolf, D. Branco, A. R. Perez-Atayde, D. Stapleton, D. Bali, Y. Xing, et al. Increased {alpha}2 Subunit-Associated AMPK Activity and PRKAG2 Cardiomyopathy Circulation, November 15, 2005; 112(20): 3140 - 3148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yang, C. J. McMahon, L. R. Smith, J. Bersola, A. M. Adesina, J. P. Breinholt, D. L. Kearney, W. J. Dreyer, S. W. Denfield, J. F. Price, et al. Danon Disease as an Underrecognized Cause of Hypertrophic Cardiomyopathy in Children Circulation, September 13, 2005; 112(11): 1612 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liao, S. Takashima, N. Maeda, N. Ouchi, K. Komamura, I. Shimomura, M. Hori, Y. Matsuzawa, T. Funahashi, and M. Kitakaze Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism Cardiovasc Res, September 1, 2005; 67(4): 705 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zou, M. Shen, M. Arad, H. He, B. Lofgren, J. S. Ingwall, C. E. Seidman, J. G. Seidman, and R. Tian N488I Mutation of the {gamma}2-Subunit Results in Bidirectional Changes in AMP-Activated Protein Kinase Activity Circ. Res., August 19, 2005; 97(4): 323 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Milan and C. A. MacRae Animal models for arrhythmias Cardiovasc Res, August 15, 2005; 67(3): 426 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Gaussin, G. E. Morley, L. Cox, A. Zwijsen, K. M. Vance, L. Emile, Y. Tian, J. Liu, C. Hong, D. Myers, et al. Alk3/Bmpr1a Receptor Is Required for Development of the Atrioventricular Canal Into Valves and Annulus Fibrosus Circ. Res., August 5, 2005; 97(3): 219 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Murphy, J. Mogensen, K. McGarry, A. Bahl, A. Evans, E. Osman, P. Syrris, G. Gorman, M. Farrell, J. L. Holton, et al. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: Natural history J. Am. Coll. Cardiol., March 15, 2005; 45(6): 922 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Meikle, J. R. McMullen, M. C. Sherwood, A. S. Lader, V. Walker, J. A. Chan, and D. J. Kwiatkowski A mouse model of cardiac rhabdomyoma generated by loss of Tsc1 in ventricular myocytes Hum. Mol. Genet., February 1, 2005; 14(3): 429 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Arad, B. J. Maron, J. M. Gorham, W. H. Johnson Jr., J. P. Saul, A. R. Perez-Atayde, P. Spirito, G. B. Wright, R. J. Kanter, C. E. Seidman, et al. Glycogen Storage Diseases Presenting as Hypertrophic Cardiomyopathy N. Engl. J. Med., January 27, 2005; 352(4): 362 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Sidhu, Y. S. Rajawat, T. G. Rami, M. H. Gollob, Z. Wang, R. Yuan, A.J. Marian, F. J. DeMayo, D. Weilbacher, G. E. Taffet, et al. Transgenic Mouse Model of Ventricular Preexcitation and Atrioventricular Reentrant Tachycardia Induced by an AMP-Activated Protein Kinase Loss-of-Function Mutation Responsible for Wolff-Parkinson-White Syndrome Circulation, January 4, 2005; 111(1): 21 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Gonzalez, R. Kumar, J. D. Mulligan, A. J. Davis, and K. W. Saupe Effects of aging on cardiac and skeletal muscle AMPK activity: basal activity, allosteric activation, and response to in vivo hypoxemia in mice Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1270 - R1275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Pederson, H. Chen, J. M. Schroeder, W. Shou, A. A. DePaoli-Roach, and P. J. Roach Abnormal Cardiac Development in the Absence of Heart Glycogen Mol. Cell. Biol., August 15, 2004; 24(16): 7179 - 7187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y. M. Chan, C.-L. M. Soltys, M. E. Young, C. G. Proud, and J. R. B. Dyck Activation of AMP-activated Protein Kinase Inhibits Protein Synthesis Associated with Hypertrophy in the Cardiac Myocyte J. Biol. Chem., July 30, 2004; 279(31): 32771 - 32779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Bilsen, P. J.H Smeets, A. J Gilde, and G. J van der Vusse Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? Cardiovasc Res, February 1, 2004; 61(2): 218 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. T. Schuldt, T. J. Hampton, V. Chu, C. A. Vogler, N. Galvin, M. D. Lessard, and J. E. Barker Electrocardiographic and other cardiac anomalies in {beta}-glucuronidase-null mice corrected by nonablative neonatal marrow transplantation PNAS, January 13, 2004; 101(2): 603 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. V. Patel, M. Arad, I. P. G. Moskowitz, C. T. Maguire, D. Branco, J. G. Seidman, C. E. Seidman, and C. I. Berul Electrophysiologic characterization and postnatal development of ventricular pre-excitation in a mouse model of cardiachypertrophy and Wolff-Parkinson-White syndrome J. Am. Coll. Cardiol., September 3, 2003; 42(5): 942 - 951. [Abstract] [Full Text] [PDF]
|
|